(Q40196281)

English

Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells

scientific article published on December 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

0 references

B-cell chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

4

object named as

Tadeusz Robak

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Piotr Smolewski

5

object named as

Piotr Smolewski

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1

object named as

Paweł Robak

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Anna Linke

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Barbara Cebula

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

publication date

1 December 2006

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

47

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

2625-2634

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Pharmacokinetic optimisation of the treatment of osteoarthritis

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Activation of the Wnt signaling pathway in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Alemtuzumab in the treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment, and clinical implications

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

In situ detection of DNA strand breaks in analysis of apoptosis by flow- and laser-scanning cytometry

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Monoclonal antibodies in the treatment of chronic lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Novel immune-based treatment strategies for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190600948147

21 January 2018

Identifiers

10.1080/10428190600948147

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40196281&oldid=1888556895"